Frequently bought together

Brand : ESOPOLE

ESOPOLE 20/MG CAP 28/CAP

52.55

Sku : I-032069
Key features
ESOPOLE 20 mg is a modified-release capsule containing the active ingredient esomeprazole 20 mg. It reduces gastric acid secretion by inhibiting the H+/K+-ATPase (proton pump) in gastric parietal cells, providing sustained acid suppression. ESOPOLE is indicated for symptomatic gastro-oesophageal reflux disease and for healing and maintenance of healed erosive esophagitis; pathological hypersecretory conditions including Zollinger-Ellison syndrome; as part of combination therapy for H. pylori eradication to reduce duodenal ulcer recurrence; and to reduce the risk of NSAID‑associated gastric ulcers in at‑risk patients. Available as prescription-only modified-release capsules in a pack of 28.
- Brand: ESOPOLE
- Active Ingredient: ESOMEPRAZOLE 20mg
- Strength: 20mg
- Dosage Form: Modified-release capsule
- Pack Size: 28 Capsules
- Route: Oral use
- Prescription Status: Prescription
- Therapeutic Class: Gastrointestinal
- Pharmacological Group: Proton Pump Inhibitors
- Drug Class: Proton Pump Inhibitor (PPI), Benzimidazole derivative
- Manufacturer: Hetero Labs Limited Unit - III
- Country of Origin: India
- SFDA Registration No.: 24-5362-21
- Shelf Life: 24 months
- Storage: store below 30°c
- Gi Condition: Acid Reflux/GERD

Frequently bought together

Description

Specification

Indications

Approved Uses

GERD (symptomatic reflux) and erosive esophagitis (healing and maintenance of healed erosive esophagitis); pathological hypersecretory conditions including Zollinger-Ellison syndrome; H. pylori eradication as part of combination therapy to reduce duodenal ulcer recurrence; risk reduction/prevention of NSAID‑associated gastric ulcer in at‑risk patients.

Off-Label Uses

Common off-label uses include laryngopharyngeal reflux (LPR), stress ulcer prophylaxis in critically ill patients (institution/protocol dependent), and as part of therapy for eosinophilic esophagitis (PPI-responsive EoE).

Side Effects

Common Side Effects

Headache, nausea, diarrhea, abdominal pain, flatulence, constipation, dry mouth, dizziness

Side Effect Frequency

Common (1-10%): headache, abdominal pain, diarrhea, nausea/vomiting, flatulence, constipation. Uncommon (0.1-1%): dizziness, dry mouth, dermatitis, pruritus, urticaria. Rare/very rare (<0.1%): hypersensitivity reactions, interstitial nephritis, severe cutaneous adverse reactions (e.g., SJS/TEN), hepatitis/liver enzyme elevations; hypomagnesemia is typically reported as rare and usually with long-term use.

Safety & Warnings

Driving Warning

Safe

Drug Interactions

Key interactions include: clopidogrel (reduced activation/antiplatelet effect), warfarin (↑INR/bleeding risk), high-dose methotrexate (↑levels/toxicity), digoxin (↑absorption), drugs needing acidic pH (e.g., ketoconazole/itraconazole, iron salts) (↓absorption), antiretrovirals (contraindicated with nelfinavir and rilpivirine; avoid/monitor with atazanavir), tacrolimus (↑levels), CYP inducers (rifampin, St. John’s wort) (↓esomeprazole exposure), and CYP2C19 substrates such as diazepam/citalopram (↑exposure in some patients).

Alcohol Interaction

Safe

Special Populations

Breastfeeding

Caution

Elderly

Standard adult dosing; no routine dose adjustment required

Kidney Impairment

No adjustment needed.

Liver Impairment

Mild-to-moderate impairment: no adjustment needed. Severe impairment (Child-Pugh Class C): do not exceed 20 mg/day.

Storage & Patient Advice

Missed Dose

Take the missed dose as soon as remembered unless it is close to the next scheduled dose; if close, skip the missed dose and resume the regular schedule. Do not double doses.

Overdose

Symptoms are usually non-specific (e.g., confusion, drowsiness, blurred vision, tachycardia, nausea/vomiting, headache); management is supportive/symptomatic, and hemodialysis is unlikely to be useful.